CARLOS RAMOS to Receptors, Antigen, T-Cell
This is a "connection" page, showing publications CARLOS RAMOS has written about Receptors, Antigen, T-Cell.
Connection Strength
3.528
-
In?Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas. Mol Ther. 2018 12 05; 26(12):2727-2737.
Score: 0.484
-
Cancer Immunotherapy Using CAR-T Cells: From the Research Bench to the Assembly Line. Biotechnol J. 2018 Feb; 13(2).
Score: 0.455
-
Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest. 2017 Sep 01; 127(9):3462-3471.
Score: 0.449
-
Clinical responses with T lymphocytes targeting malignancy-associated ? light chains. J Clin Invest. 2016 07 01; 126(7):2588-96.
Score: 0.413
-
CAR-T Cell Therapy for Lymphoma. Annu Rev Med. 2016; 67:165-83.
Score: 0.391
-
Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Ther. 2011 Jul; 11(7):855-73.
Score: 0.289
-
Chimeric Antigen Receptor T Cells in Hodgkin and T-Cell Lymphomas. Hematol Oncol Clin North Am. 2023 12; 37(6):1107-1124.
Score: 0.168
-
Cellular Immunotherapy in Lymphoma: Beyond CART Cells. Curr Treat Options Oncol. 2020 02 11; 21(3):21.
Score: 0.133
-
Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity. J Immunother Cancer. 2019 11 28; 7(1):330.
Score: 0.131
-
T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells. Clin Cancer Res. 2019 12 15; 25(24):7340-7350.
Score: 0.130
-
The CNS can be a safe space for CARs. Blood. 2019 09 12; 134(11):845-846.
Score: 0.130
-
The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 2018 May; 16(5):375-386.
Score: 0.118
-
Expanding Accessibility to CD19-CAR T Cells: Commercializing a "Boutique" Therapy. Mol Ther. 2017 01 04; 25(1):8-9.
Score: 0.108
-
Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood. 2015 Jun 18; 125(25):3905-16.
Score: 0.096
-
The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma. Sci Transl Med. 2020 07 29; 12(554).
Score: 0.034